2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasm Metastasis
2
Sarcoma
1
Recurrence
1
Prostatic Hyperplasia
1
Multiple Endocrine Neoplasia Type 1
1
Liver Diseases
1
Leiomyoma
1
Hyperplasia
1
Head and Neck Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
5
Blood Specimen Collection
4
lenvatinib
3
sintilimab
2
pembrolizumab
2
ledipasvir, sofosbuvir drug combination
2
halofantrine
2
camrelizumab
2
atezolizumab
2
Liver Transplantation
2
Immunotherapy
2
Control Groups
2
Bevacizumab
2
Antibodies
2
veliparib
1
trifluridine tipiracil drug combination
1
trametinib
1
toripalimab
1
titanium silicide
1
tislelizumab
1
rubitecan
1
repotrectinib
1
pevonedistat
1
ozanimod
1
linifanib
1
genexol-PM
1
gadolinium ethoxybenzyl DTPA
1
fluorocholine
1
fisogatinib
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Liver Diseases
×
Microspheres
×
Clear all
NCT02208804
2016-11-09
SIM
UMC Utrecht
Phase 2/3
Unknown
25 enrolled